Clinical Trials Directory

Trials / Unknown

UnknownNCT02438020

Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity

Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Juan Pablo Castanedo-Cazares · Academic / Other
Sex
All
Age
8 Years – 17 Years
Healthy volunteers
Not accepted

Summary

Obesity is often accompanied by insulin resistance and/or hyperinsulinemia. Acanthosis nigricans (AN) is a skin condition commonly present on the neck of obese children. Metformin is a useful drug for conditions characterized by insulin resistance.The aim of this study is to compare the efficacy of metformin versus placebo on AN lesions of the neck as well as their effects on metabolic and anthropometric variables in a sample of obese children. This is a 12-week randomized, double-blind randomized trial involving obese children with AN to receive either metformin or placebo. Evaluations will be performed every three weeks. Clinical, histological and colorimetric assessments of AN lesions will be compared initially and at the conclusion of the study.

Detailed description

Acanthosis nigricans (AN) are lesions affecting localized areas of the skin in persons with obesity and/or hyperinsulinemia. Roughening of the skin is related with histological papillomatosis and the skin darkening is due to hyperkeratosis. Biochemical mechanisms for developing this hyperplastic lesion involve local cutaneous growth factors. Nearly 40% of Native American teenagers have acanthosis nigricans, whereas about 13% of African American, 6% of Hispanic, and less than 1% of white, non-Hispanic children aged 10-19 have clinically apparent acanthosis nigricans. AN is a clinical surrogate of laboratory-documented hyperinsulinemia. The aim of this study is to compare the efficacy of metformin versus placebo on AN lesions of the neck as well as their effects on metabolic (HOMA, triglycerides, cholesterol) and anthropometric variables (BMI, waist) in a sample of obese children. This is a 12-week randomized, double-blind randomized trial involving obese children with AN to receive either metformin or placebo. Evaluations will be performed every three weeks. Clinical, histological and colorimetric assessments of AN lesions will be compared initially and at the conclusion of the study. Burke´s scale, papillomatosis and hyperkeratosis, and the L\* axis of will be used to measure the AN improvement.

Conditions

Interventions

TypeNameDescription
DRUGMetforminOne tablet of 500 mg will be ingested before the main meal
OTHERPlaceboA placebo tablet will be ingested daily before main meal.

Timeline

Start date
2015-06-01
Primary completion
2016-06-01
Completion
2016-10-01
First posted
2015-05-08
Last updated
2015-05-08

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT02438020. Inclusion in this directory is not an endorsement.